Basking Biosciences, founded with the mission to revolutionize acute thrombosis treatment, focuses on developing therapies to restore blood flow to the brain during ischemic strokes. Their core product, a first-in-class reversible RNA aptamer targeting von Willebrand Factor, aims to be a safer and more effective first-line therapy. This innovative approach is designed to prevent hemorrhage and long-term damage, significantly expanding the population that can receive acute revascularization therapy.
Notable affiliated individuals and investors include experts in stroke therapy and biotechnology. The company’s key achievement is the development of their drug candidate BB-031, which is set to enter Phase II clinical trials in 2024. Basking Biosciences has made a significant impact by addressing critical gaps in stroke treatment, potentially transforming the standard of care for acute ischemic stroke patients.
